Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyteir Therapeutics Inc
(NQ:
CYT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cyteir Therapeutics Inc
< Previous
1
2
3
Next >
Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference
May 04, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality
May 03, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Names Adam Veness General Counsel
April 25, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022
April 18, 2022
From
Cyteir Therapeutics
Via
Business Wire
68 Biggest Movers From Yesterday
April 19, 2022
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...
Via
Benzinga
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
March 16, 2022
From
Cyteir Therapeutics
Via
Business Wire
64 Biggest Movers From Yesterday
March 18, 2022
Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co. Cuentas Inc. (NASDAQ:...
Via
Benzinga
Earnings Scheduled For March 16, 2022
March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 09, 2022
During Wednesday's session, 35 companies made new 52-week lows. 52-Week High And Low Highlights: The company with the largest market cap to set a new 52-week low was...
Via
Benzinga
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors
February 24, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851
February 08, 2022
From
Cyteir Therapeutics
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2022
February 07, 2022
Upgrades For Enova International Inc (NYSE:ENVA), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61,...
Via
Benzinga
Cyteir Therapeutics Announces the Appointment of John F. Thero to Board of Directors
February 07, 2022
From
Cyteir Therapeutics
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
January 12, 2022
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on...
Via
Benzinga
54 Biggest Movers From Yesterday
February 03, 2022
Gainers MDJM Ltd (NASDAQ: MDJH) shares surged 35.6% to close at $2.44 on Wednesday after gaining 10% on Tuesday. GWG Holdings, Inc. (NASDAQ: GWGH) gained 31.6% to settle at $4.50...
Via
Benzinga
Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851
January 12, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors
December 16, 2021
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 12, 2021
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference
November 01, 2021
From
Cyteir Therapeutics
Via
Business Wire
52 Biggest Movers From Yesterday
December 01, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...
Via
Benzinga
Exposures
Product Safety
Cyteir Therapeutics Selected to Join Russell 2000® Index
September 20, 2021
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
September 01, 2021
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
August 09, 2021
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
August 02, 2021
From
Cyteir Therapeutics
Via
Business Wire
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
July 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...
Via
Benzinga
Exposures
Product Safety
61 Biggest Movers From Yesterday
July 22, 2021
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's...
Via
Benzinga
These 3 New Biotechs Have Differentiated Platforms, Technology: BofA
July 13, 2021
Following the expiry of IPO quiet periods for the recently listed Ambrx Biopharma Inc. (NASDAQ:
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.